Cephalon’s Nuvigil Filing Remains On Schedule For First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon's modafinil follow-on Nuvigil (armodafinil) showed statistical significance in each of four pivotal studies intended to support a first-quarter NDA filing, the firm announced Feb. 10
You may also be interested in...
Cephalon Expects To Reduce Modafinil Price For ADHD By About 40%
The company says it will price modafinil for attention deficit/hyperactivity disorder in-line with other branded products on the market at the time of launch. Based on current prices, Cephalon expects to reduce modafinil's price for ADHD to $3-$3.50 from the current $6 per pill price for Provigil.
Cephalon Expects To Reduce Modafinil Price For ADHD By About 40%
The company says it will price modafinil for attention deficit/hyperactivity disorder in-line with other branded products on the market at the time of launch. Based on current prices, Cephalon expects to reduce modafinil's price for ADHD to $3-$3.50 from the current $6 per pill price for Provigil.
Cephalon's Nuvigil Will Be Discounted To Provigil, But Not "At A Low Price"
Cephalon will encourage patients to switch to follow-on Nuvigil by increasing the Provigil price "dramatically" ahead of generic competition. The company will file the Nuvigil NDA within the next couple of weeks.